The health sector is one of the keys to sustainable development. Although it is directly
related to only one Sustainable Development Goal (Goal 3,“Ensuring a healthy life and …

Innovative reimbursement mechanisms have long been considered potential solutions to the
data uncertainty associated with one-off, high-value gene therapies that have long-term …

Background: The experience of Kymriah® and Yescarta® provides real-world examples of
how health-care systems approach and manage the reimbursement of one-off, high-cost …

Background Advanced therapy medicinal products (ATMPs) represent an important
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …

This last decade has been marked by significant advances in the development of cell and
gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies …

The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in
Health and Medicine, has been used to specify the required methodological features of …

Tissue Engineering (TE) is a branch of Regenerative Medicine (RM) that combines stem
cells and biomaterial scaffolds to create living tissue constructs to restore patients' organs …

Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-
engineered therapies have demonstrated enormous therapeutic benefits. However, their …

The available evidence on relative effectiveness and risks of new health technologies is
often limited at the time of health technology assessment (HTA). Additionally, a wide variety …